| Patient/tumour characteristic . | Treatment modality . | P . | ||||
|---|---|---|---|---|---|---|
| sBCS + RTx, 8537 (60.2) . | OBCS + RTx, 360 (2.5) . | Mx + RTx, 2953 (20.9) . | Mx − RTx, 2332 (16.4) . | Total, n = 14 182 . | ||
| Age at diagnosis (years) | <0.001 | |||||
| <50 | 1412 (16.5) | 118 (32.8) | 882 (29.9) | 336 (14.4) | 2748 (19.3) | |
| 50–69 | 5625 (65.9) | 220 (61.1) | 1374 (46.5) | 1045 (44.8) | 8264 (58.3) | |
| ≥70 | 1500 (17.6) | 22 (6.1) | 697 (23.6) | 951 (40.8) | 3170 (22.4) | |
| Median (range) | 61 (23–92) | 53 (23–80) | 57 (25–94) | 67 (22–96) | 61 (22–96) | |
| Referral | <0.001 | |||||
| Symptomatic | 4135 (48.4) | 237 (65.8) | 2330 (78.9) | 1493 (64.0) | 8195 (57.8) | |
| Screening | 3875 (45.4) | 100 (27.8) | 394 (13.3) | 543 (23.3) | 4912 (34.6) | |
| Other | 527 (6.2) | 23 (6.4) | 229 (7.8) | 296 (12.7) | 1075 (7.6) | |
| Year of diagnosis | <0.001 | |||||
| 2010–2011 | 1022 (12.0) | 28 (7.8) | 423 (14.3) | 364 (15.6) | 1837 (13.0) | |
| 2012–2013 | 1887 (22.1) | 39 (10.8) | 714 (24.2) | 566 (24.3) | 3206 (22.6) | |
| 2014–2015 | 1908 (22.3) | 98 (27.2) | 655 (22.2) | 542 (23.2) | 3203 (22.6) | |
| 2016–2017 | 1815 (21.3) | 103 (28.6) | 595 (20.1) | 432 (18.5) | 2945 (20.8) | |
| 2018–2019 | 1905 (22.3) | 92 (25.6) | 566 (19.2) | 428 (18.4) | 2991 (21.1) | |
| SIMD category | 0.006 | |||||
| Most affluent | 1668 (19.6) | 90 (25.1) | 569 (19.4) | 408 (17.5) | 2735 (19.4) | |
| Affluent | 1449 (17.1) | 64 (17.9) | 489 (16.7) | 394 (17.0) | 2396 (17.0) | |
| Intermediate | 1518 (17.9) | 71 (19.8) | 505 (17.2) | 378 (16.3) | 2472 (17.5) | |
| Deprived | 1739 (20.5) | 64 (17.9) | 608 (20.7) | 525 (22.6) | 2936 (20.8) | |
| Most deprived | 2116 (24.9) | 69 (19.3) | 763 (26.0) | 615 (26.5) | 3563 (25.3) | |
| Bilateral breast cancer | <0.001 | |||||
| No | 8421 (98.9) | 354 (98.3) | 2846 (97.1) | 2253 (96.9) | 13 874 (98.2) | |
| Yes | 96 (1.1) | 6 (1.7) | 86 (2.9) | 71 (3.1) | 259 (1.8) | |
| T stage* | <0.001 | |||||
| T1 | 5657 (66.3) | 112 (31.3) | 462 (16.1) | 1040 (44.6) | 7271 (51.6) | |
| T2 | 2704 (31.7) | 209 (58.4) | 1578 (54.8) | 1201 (51.5) | 5692 (40.3) | |
| ≥T3 | 171 (2.0) | 37 (10.3) | 837 (29.1) | 90 (3.9) | 1135 (8.1) | |
| N stage* | <0.001 | |||||
| N0 | 6383 (75.0) | 255 (70.8) | 654 (22.2) | 1917 (85.2) | 9209 (65.5) | |
| N1 | 1867 (21.9) | 87 (24.2) | 1704 (58.1) | 266 (11.8) | 3924 (27.9) | |
| N2 | 180 (2.1) | 13 (3.6) | 386 (13.2) | 46 (2.0) | 625 (4.4) | |
| N3 | 83 (1.0) | 5 (1.4) | 191 (6.5) | 22 (1.0) | 301 (2.1) | |
| Prognostic stage | <0.001 | |||||
| I | 5555 (65.1) | 108 (30.0) | 408 (13.8) | 1009 (43.3) | 7080 (49.9) | |
| II | 2791 (32.7) | 230 (63.9) | 1856 (62.9) | 1230 (52.7) | 6107 (43.1) | |
| III | 191 (2.2) | 22 (6.1) | 689 (23.3) | 93 (4.0) | 995 (7.0) | |
| Histological subtype | <0.001 | |||||
| Ductal | 7137 (83.6) | 295 (81.9) | 2238 (75.8) | 1775 (76.1) | 11 445 (80.7) | |
| Lobular | 754 (8.8) | 48 (13.3) | 507 (17.2) | 360 (15.4) | 1669 (11.8) | |
| Other | 643 (7.5) | 17 (4.7) | 207 (7.0) | 197 (8.4) | 1064 (7.5) | |
| Tumour grade | <0.001 | |||||
| 1 | 1287 (15.3) | 22 (6.3) | 114 (4.1) | 218 (9.5) | 1641 (11.8) | |
| 2 | 4035 (47.9) | 159 (45.3) | 1211 (43.3) | 1123 (48.8) | 6528 (47.1) | |
| 3 | 3095 (36.8) | 170 (48.4) | 1473 (52.6) | 959 (41.7) | 5697 (41.1) | |
| Subtype | <0.001 | |||||
| ER+HER2− | 6157 (72.1) | 231 (64.2) | 1763 (59.7) | 1503 (64.5) | 9654 (68.1) | |
| ER+HER2+ | 696 (8.2) | 52 (14.4) | 401 (13.6) | 213 (9.1) | 1362 (9.6) | |
| ER−HER2+ | 274 (3.2) | 15 (4.2) | 207 (7.0) | 113 (4.8) | 609 (4.3) | |
| ER−HER2− | 592 (6.9) | 18 (5.0) | 254 (8.6) | 190 (8.1) | 1054 (7.4) | |
| Inconclusive | 818 (9.6) | 44 (12.2) | 328 (11.1) | 313 (13.4) | 1503 (10.6) | |
| Chemotherapy | <0.001 | |||||
| No | 5548 (65.0) | 147 (40.8) | 863 (29.2) | 1767 (75.8) | 8325 (58.7) | |
| Yes | 2989 (35.0) | 213 (59.2) | 2090 (70.8) | 565 (24.2) | 5857 (41.3) | |
| Biological therapy | <0.001 | |||||
| No | 7681 (90.0) | 287 (79.7) | 2369 (80.2) | 2116 (90.7) | 12 453 (87.8) | |
| Yes | 856 (10.0) | 73 (20.3) | 584 (19.8) | 216 (9.3) | 1729 (12.2) | |
| Endocrine therapy | <0.001 | |||||
| No | 1333 (15.6) | 61 (16.9) | 688 (23.3) | 519 (22.3) | 2601 (18.3) | |
| Yes | 7204 (84.4) | 299 (83.1) | 2265 (76.7) | 1813 (77.7) | 11 581 (81.7) | |
| Deaths | ||||||
| Overall | 1265 (14.8) | 37 (10.3) | 926 (31.4) | 734 (31.5) | 2962 (20.9) | <0.001 |
| Breast cancer-specific | 450 (5.3) | 26 (7.2) | 604 (20.5) | 246 (10.5) | 1326 (9.3) | <0.001 |
| Patient/tumour characteristic . | Treatment modality . | P . | ||||
|---|---|---|---|---|---|---|
| sBCS + RTx, 8537 (60.2) . | OBCS + RTx, 360 (2.5) . | Mx + RTx, 2953 (20.9) . | Mx − RTx, 2332 (16.4) . | Total, n = 14 182 . | ||
| Age at diagnosis (years) | <0.001 | |||||
| <50 | 1412 (16.5) | 118 (32.8) | 882 (29.9) | 336 (14.4) | 2748 (19.3) | |
| 50–69 | 5625 (65.9) | 220 (61.1) | 1374 (46.5) | 1045 (44.8) | 8264 (58.3) | |
| ≥70 | 1500 (17.6) | 22 (6.1) | 697 (23.6) | 951 (40.8) | 3170 (22.4) | |
| Median (range) | 61 (23–92) | 53 (23–80) | 57 (25–94) | 67 (22–96) | 61 (22–96) | |
| Referral | <0.001 | |||||
| Symptomatic | 4135 (48.4) | 237 (65.8) | 2330 (78.9) | 1493 (64.0) | 8195 (57.8) | |
| Screening | 3875 (45.4) | 100 (27.8) | 394 (13.3) | 543 (23.3) | 4912 (34.6) | |
| Other | 527 (6.2) | 23 (6.4) | 229 (7.8) | 296 (12.7) | 1075 (7.6) | |
| Year of diagnosis | <0.001 | |||||
| 2010–2011 | 1022 (12.0) | 28 (7.8) | 423 (14.3) | 364 (15.6) | 1837 (13.0) | |
| 2012–2013 | 1887 (22.1) | 39 (10.8) | 714 (24.2) | 566 (24.3) | 3206 (22.6) | |
| 2014–2015 | 1908 (22.3) | 98 (27.2) | 655 (22.2) | 542 (23.2) | 3203 (22.6) | |
| 2016–2017 | 1815 (21.3) | 103 (28.6) | 595 (20.1) | 432 (18.5) | 2945 (20.8) | |
| 2018–2019 | 1905 (22.3) | 92 (25.6) | 566 (19.2) | 428 (18.4) | 2991 (21.1) | |
| SIMD category | 0.006 | |||||
| Most affluent | 1668 (19.6) | 90 (25.1) | 569 (19.4) | 408 (17.5) | 2735 (19.4) | |
| Affluent | 1449 (17.1) | 64 (17.9) | 489 (16.7) | 394 (17.0) | 2396 (17.0) | |
| Intermediate | 1518 (17.9) | 71 (19.8) | 505 (17.2) | 378 (16.3) | 2472 (17.5) | |
| Deprived | 1739 (20.5) | 64 (17.9) | 608 (20.7) | 525 (22.6) | 2936 (20.8) | |
| Most deprived | 2116 (24.9) | 69 (19.3) | 763 (26.0) | 615 (26.5) | 3563 (25.3) | |
| Bilateral breast cancer | <0.001 | |||||
| No | 8421 (98.9) | 354 (98.3) | 2846 (97.1) | 2253 (96.9) | 13 874 (98.2) | |
| Yes | 96 (1.1) | 6 (1.7) | 86 (2.9) | 71 (3.1) | 259 (1.8) | |
| T stage* | <0.001 | |||||
| T1 | 5657 (66.3) | 112 (31.3) | 462 (16.1) | 1040 (44.6) | 7271 (51.6) | |
| T2 | 2704 (31.7) | 209 (58.4) | 1578 (54.8) | 1201 (51.5) | 5692 (40.3) | |
| ≥T3 | 171 (2.0) | 37 (10.3) | 837 (29.1) | 90 (3.9) | 1135 (8.1) | |
| N stage* | <0.001 | |||||
| N0 | 6383 (75.0) | 255 (70.8) | 654 (22.2) | 1917 (85.2) | 9209 (65.5) | |
| N1 | 1867 (21.9) | 87 (24.2) | 1704 (58.1) | 266 (11.8) | 3924 (27.9) | |
| N2 | 180 (2.1) | 13 (3.6) | 386 (13.2) | 46 (2.0) | 625 (4.4) | |
| N3 | 83 (1.0) | 5 (1.4) | 191 (6.5) | 22 (1.0) | 301 (2.1) | |
| Prognostic stage | <0.001 | |||||
| I | 5555 (65.1) | 108 (30.0) | 408 (13.8) | 1009 (43.3) | 7080 (49.9) | |
| II | 2791 (32.7) | 230 (63.9) | 1856 (62.9) | 1230 (52.7) | 6107 (43.1) | |
| III | 191 (2.2) | 22 (6.1) | 689 (23.3) | 93 (4.0) | 995 (7.0) | |
| Histological subtype | <0.001 | |||||
| Ductal | 7137 (83.6) | 295 (81.9) | 2238 (75.8) | 1775 (76.1) | 11 445 (80.7) | |
| Lobular | 754 (8.8) | 48 (13.3) | 507 (17.2) | 360 (15.4) | 1669 (11.8) | |
| Other | 643 (7.5) | 17 (4.7) | 207 (7.0) | 197 (8.4) | 1064 (7.5) | |
| Tumour grade | <0.001 | |||||
| 1 | 1287 (15.3) | 22 (6.3) | 114 (4.1) | 218 (9.5) | 1641 (11.8) | |
| 2 | 4035 (47.9) | 159 (45.3) | 1211 (43.3) | 1123 (48.8) | 6528 (47.1) | |
| 3 | 3095 (36.8) | 170 (48.4) | 1473 (52.6) | 959 (41.7) | 5697 (41.1) | |
| Subtype | <0.001 | |||||
| ER+HER2− | 6157 (72.1) | 231 (64.2) | 1763 (59.7) | 1503 (64.5) | 9654 (68.1) | |
| ER+HER2+ | 696 (8.2) | 52 (14.4) | 401 (13.6) | 213 (9.1) | 1362 (9.6) | |
| ER−HER2+ | 274 (3.2) | 15 (4.2) | 207 (7.0) | 113 (4.8) | 609 (4.3) | |
| ER−HER2− | 592 (6.9) | 18 (5.0) | 254 (8.6) | 190 (8.1) | 1054 (7.4) | |
| Inconclusive | 818 (9.6) | 44 (12.2) | 328 (11.1) | 313 (13.4) | 1503 (10.6) | |
| Chemotherapy | <0.001 | |||||
| No | 5548 (65.0) | 147 (40.8) | 863 (29.2) | 1767 (75.8) | 8325 (58.7) | |
| Yes | 2989 (35.0) | 213 (59.2) | 2090 (70.8) | 565 (24.2) | 5857 (41.3) | |
| Biological therapy | <0.001 | |||||
| No | 7681 (90.0) | 287 (79.7) | 2369 (80.2) | 2116 (90.7) | 12 453 (87.8) | |
| Yes | 856 (10.0) | 73 (20.3) | 584 (19.8) | 216 (9.3) | 1729 (12.2) | |
| Endocrine therapy | <0.001 | |||||
| No | 1333 (15.6) | 61 (16.9) | 688 (23.3) | 519 (22.3) | 2601 (18.3) | |
| Yes | 7204 (84.4) | 299 (83.1) | 2265 (76.7) | 1813 (77.7) | 11 581 (81.7) | |
| Deaths | ||||||
| Overall | 1265 (14.8) | 37 (10.3) | 926 (31.4) | 734 (31.5) | 2962 (20.9) | <0.001 |
| Breast cancer-specific | 450 (5.3) | 26 (7.2) | 604 (20.5) | 246 (10.5) | 1326 (9.3) | <0.001 |
Values are n (%) unless otherwise indicated. *Pathological stage used for primary surgery patients and pretreatment clinical stage used for neoadjuvant chemotherapy patients. sBCS, standard breast-conserving surgery; RTx, radiotherapy; OBCS, oncoplastic breast-conserving surgery; MTx, mastectomy; SMID, Scottish Index of Multiple Deprivation; ER, oestrogen receptor; HER2, human epidermal growth factor receptor-2.
| Patient/tumour characteristic . | Treatment modality . | P . | ||||
|---|---|---|---|---|---|---|
| sBCS + RTx, 8537 (60.2) . | OBCS + RTx, 360 (2.5) . | Mx + RTx, 2953 (20.9) . | Mx − RTx, 2332 (16.4) . | Total, n = 14 182 . | ||
| Age at diagnosis (years) | <0.001 | |||||
| <50 | 1412 (16.5) | 118 (32.8) | 882 (29.9) | 336 (14.4) | 2748 (19.3) | |
| 50–69 | 5625 (65.9) | 220 (61.1) | 1374 (46.5) | 1045 (44.8) | 8264 (58.3) | |
| ≥70 | 1500 (17.6) | 22 (6.1) | 697 (23.6) | 951 (40.8) | 3170 (22.4) | |
| Median (range) | 61 (23–92) | 53 (23–80) | 57 (25–94) | 67 (22–96) | 61 (22–96) | |
| Referral | <0.001 | |||||
| Symptomatic | 4135 (48.4) | 237 (65.8) | 2330 (78.9) | 1493 (64.0) | 8195 (57.8) | |
| Screening | 3875 (45.4) | 100 (27.8) | 394 (13.3) | 543 (23.3) | 4912 (34.6) | |
| Other | 527 (6.2) | 23 (6.4) | 229 (7.8) | 296 (12.7) | 1075 (7.6) | |
| Year of diagnosis | <0.001 | |||||
| 2010–2011 | 1022 (12.0) | 28 (7.8) | 423 (14.3) | 364 (15.6) | 1837 (13.0) | |
| 2012–2013 | 1887 (22.1) | 39 (10.8) | 714 (24.2) | 566 (24.3) | 3206 (22.6) | |
| 2014–2015 | 1908 (22.3) | 98 (27.2) | 655 (22.2) | 542 (23.2) | 3203 (22.6) | |
| 2016–2017 | 1815 (21.3) | 103 (28.6) | 595 (20.1) | 432 (18.5) | 2945 (20.8) | |
| 2018–2019 | 1905 (22.3) | 92 (25.6) | 566 (19.2) | 428 (18.4) | 2991 (21.1) | |
| SIMD category | 0.006 | |||||
| Most affluent | 1668 (19.6) | 90 (25.1) | 569 (19.4) | 408 (17.5) | 2735 (19.4) | |
| Affluent | 1449 (17.1) | 64 (17.9) | 489 (16.7) | 394 (17.0) | 2396 (17.0) | |
| Intermediate | 1518 (17.9) | 71 (19.8) | 505 (17.2) | 378 (16.3) | 2472 (17.5) | |
| Deprived | 1739 (20.5) | 64 (17.9) | 608 (20.7) | 525 (22.6) | 2936 (20.8) | |
| Most deprived | 2116 (24.9) | 69 (19.3) | 763 (26.0) | 615 (26.5) | 3563 (25.3) | |
| Bilateral breast cancer | <0.001 | |||||
| No | 8421 (98.9) | 354 (98.3) | 2846 (97.1) | 2253 (96.9) | 13 874 (98.2) | |
| Yes | 96 (1.1) | 6 (1.7) | 86 (2.9) | 71 (3.1) | 259 (1.8) | |
| T stage* | <0.001 | |||||
| T1 | 5657 (66.3) | 112 (31.3) | 462 (16.1) | 1040 (44.6) | 7271 (51.6) | |
| T2 | 2704 (31.7) | 209 (58.4) | 1578 (54.8) | 1201 (51.5) | 5692 (40.3) | |
| ≥T3 | 171 (2.0) | 37 (10.3) | 837 (29.1) | 90 (3.9) | 1135 (8.1) | |
| N stage* | <0.001 | |||||
| N0 | 6383 (75.0) | 255 (70.8) | 654 (22.2) | 1917 (85.2) | 9209 (65.5) | |
| N1 | 1867 (21.9) | 87 (24.2) | 1704 (58.1) | 266 (11.8) | 3924 (27.9) | |
| N2 | 180 (2.1) | 13 (3.6) | 386 (13.2) | 46 (2.0) | 625 (4.4) | |
| N3 | 83 (1.0) | 5 (1.4) | 191 (6.5) | 22 (1.0) | 301 (2.1) | |
| Prognostic stage | <0.001 | |||||
| I | 5555 (65.1) | 108 (30.0) | 408 (13.8) | 1009 (43.3) | 7080 (49.9) | |
| II | 2791 (32.7) | 230 (63.9) | 1856 (62.9) | 1230 (52.7) | 6107 (43.1) | |
| III | 191 (2.2) | 22 (6.1) | 689 (23.3) | 93 (4.0) | 995 (7.0) | |
| Histological subtype | <0.001 | |||||
| Ductal | 7137 (83.6) | 295 (81.9) | 2238 (75.8) | 1775 (76.1) | 11 445 (80.7) | |
| Lobular | 754 (8.8) | 48 (13.3) | 507 (17.2) | 360 (15.4) | 1669 (11.8) | |
| Other | 643 (7.5) | 17 (4.7) | 207 (7.0) | 197 (8.4) | 1064 (7.5) | |
| Tumour grade | <0.001 | |||||
| 1 | 1287 (15.3) | 22 (6.3) | 114 (4.1) | 218 (9.5) | 1641 (11.8) | |
| 2 | 4035 (47.9) | 159 (45.3) | 1211 (43.3) | 1123 (48.8) | 6528 (47.1) | |
| 3 | 3095 (36.8) | 170 (48.4) | 1473 (52.6) | 959 (41.7) | 5697 (41.1) | |
| Subtype | <0.001 | |||||
| ER+HER2− | 6157 (72.1) | 231 (64.2) | 1763 (59.7) | 1503 (64.5) | 9654 (68.1) | |
| ER+HER2+ | 696 (8.2) | 52 (14.4) | 401 (13.6) | 213 (9.1) | 1362 (9.6) | |
| ER−HER2+ | 274 (3.2) | 15 (4.2) | 207 (7.0) | 113 (4.8) | 609 (4.3) | |
| ER−HER2− | 592 (6.9) | 18 (5.0) | 254 (8.6) | 190 (8.1) | 1054 (7.4) | |
| Inconclusive | 818 (9.6) | 44 (12.2) | 328 (11.1) | 313 (13.4) | 1503 (10.6) | |
| Chemotherapy | <0.001 | |||||
| No | 5548 (65.0) | 147 (40.8) | 863 (29.2) | 1767 (75.8) | 8325 (58.7) | |
| Yes | 2989 (35.0) | 213 (59.2) | 2090 (70.8) | 565 (24.2) | 5857 (41.3) | |
| Biological therapy | <0.001 | |||||
| No | 7681 (90.0) | 287 (79.7) | 2369 (80.2) | 2116 (90.7) | 12 453 (87.8) | |
| Yes | 856 (10.0) | 73 (20.3) | 584 (19.8) | 216 (9.3) | 1729 (12.2) | |
| Endocrine therapy | <0.001 | |||||
| No | 1333 (15.6) | 61 (16.9) | 688 (23.3) | 519 (22.3) | 2601 (18.3) | |
| Yes | 7204 (84.4) | 299 (83.1) | 2265 (76.7) | 1813 (77.7) | 11 581 (81.7) | |
| Deaths | ||||||
| Overall | 1265 (14.8) | 37 (10.3) | 926 (31.4) | 734 (31.5) | 2962 (20.9) | <0.001 |
| Breast cancer-specific | 450 (5.3) | 26 (7.2) | 604 (20.5) | 246 (10.5) | 1326 (9.3) | <0.001 |
| Patient/tumour characteristic . | Treatment modality . | P . | ||||
|---|---|---|---|---|---|---|
| sBCS + RTx, 8537 (60.2) . | OBCS + RTx, 360 (2.5) . | Mx + RTx, 2953 (20.9) . | Mx − RTx, 2332 (16.4) . | Total, n = 14 182 . | ||
| Age at diagnosis (years) | <0.001 | |||||
| <50 | 1412 (16.5) | 118 (32.8) | 882 (29.9) | 336 (14.4) | 2748 (19.3) | |
| 50–69 | 5625 (65.9) | 220 (61.1) | 1374 (46.5) | 1045 (44.8) | 8264 (58.3) | |
| ≥70 | 1500 (17.6) | 22 (6.1) | 697 (23.6) | 951 (40.8) | 3170 (22.4) | |
| Median (range) | 61 (23–92) | 53 (23–80) | 57 (25–94) | 67 (22–96) | 61 (22–96) | |
| Referral | <0.001 | |||||
| Symptomatic | 4135 (48.4) | 237 (65.8) | 2330 (78.9) | 1493 (64.0) | 8195 (57.8) | |
| Screening | 3875 (45.4) | 100 (27.8) | 394 (13.3) | 543 (23.3) | 4912 (34.6) | |
| Other | 527 (6.2) | 23 (6.4) | 229 (7.8) | 296 (12.7) | 1075 (7.6) | |
| Year of diagnosis | <0.001 | |||||
| 2010–2011 | 1022 (12.0) | 28 (7.8) | 423 (14.3) | 364 (15.6) | 1837 (13.0) | |
| 2012–2013 | 1887 (22.1) | 39 (10.8) | 714 (24.2) | 566 (24.3) | 3206 (22.6) | |
| 2014–2015 | 1908 (22.3) | 98 (27.2) | 655 (22.2) | 542 (23.2) | 3203 (22.6) | |
| 2016–2017 | 1815 (21.3) | 103 (28.6) | 595 (20.1) | 432 (18.5) | 2945 (20.8) | |
| 2018–2019 | 1905 (22.3) | 92 (25.6) | 566 (19.2) | 428 (18.4) | 2991 (21.1) | |
| SIMD category | 0.006 | |||||
| Most affluent | 1668 (19.6) | 90 (25.1) | 569 (19.4) | 408 (17.5) | 2735 (19.4) | |
| Affluent | 1449 (17.1) | 64 (17.9) | 489 (16.7) | 394 (17.0) | 2396 (17.0) | |
| Intermediate | 1518 (17.9) | 71 (19.8) | 505 (17.2) | 378 (16.3) | 2472 (17.5) | |
| Deprived | 1739 (20.5) | 64 (17.9) | 608 (20.7) | 525 (22.6) | 2936 (20.8) | |
| Most deprived | 2116 (24.9) | 69 (19.3) | 763 (26.0) | 615 (26.5) | 3563 (25.3) | |
| Bilateral breast cancer | <0.001 | |||||
| No | 8421 (98.9) | 354 (98.3) | 2846 (97.1) | 2253 (96.9) | 13 874 (98.2) | |
| Yes | 96 (1.1) | 6 (1.7) | 86 (2.9) | 71 (3.1) | 259 (1.8) | |
| T stage* | <0.001 | |||||
| T1 | 5657 (66.3) | 112 (31.3) | 462 (16.1) | 1040 (44.6) | 7271 (51.6) | |
| T2 | 2704 (31.7) | 209 (58.4) | 1578 (54.8) | 1201 (51.5) | 5692 (40.3) | |
| ≥T3 | 171 (2.0) | 37 (10.3) | 837 (29.1) | 90 (3.9) | 1135 (8.1) | |
| N stage* | <0.001 | |||||
| N0 | 6383 (75.0) | 255 (70.8) | 654 (22.2) | 1917 (85.2) | 9209 (65.5) | |
| N1 | 1867 (21.9) | 87 (24.2) | 1704 (58.1) | 266 (11.8) | 3924 (27.9) | |
| N2 | 180 (2.1) | 13 (3.6) | 386 (13.2) | 46 (2.0) | 625 (4.4) | |
| N3 | 83 (1.0) | 5 (1.4) | 191 (6.5) | 22 (1.0) | 301 (2.1) | |
| Prognostic stage | <0.001 | |||||
| I | 5555 (65.1) | 108 (30.0) | 408 (13.8) | 1009 (43.3) | 7080 (49.9) | |
| II | 2791 (32.7) | 230 (63.9) | 1856 (62.9) | 1230 (52.7) | 6107 (43.1) | |
| III | 191 (2.2) | 22 (6.1) | 689 (23.3) | 93 (4.0) | 995 (7.0) | |
| Histological subtype | <0.001 | |||||
| Ductal | 7137 (83.6) | 295 (81.9) | 2238 (75.8) | 1775 (76.1) | 11 445 (80.7) | |
| Lobular | 754 (8.8) | 48 (13.3) | 507 (17.2) | 360 (15.4) | 1669 (11.8) | |
| Other | 643 (7.5) | 17 (4.7) | 207 (7.0) | 197 (8.4) | 1064 (7.5) | |
| Tumour grade | <0.001 | |||||
| 1 | 1287 (15.3) | 22 (6.3) | 114 (4.1) | 218 (9.5) | 1641 (11.8) | |
| 2 | 4035 (47.9) | 159 (45.3) | 1211 (43.3) | 1123 (48.8) | 6528 (47.1) | |
| 3 | 3095 (36.8) | 170 (48.4) | 1473 (52.6) | 959 (41.7) | 5697 (41.1) | |
| Subtype | <0.001 | |||||
| ER+HER2− | 6157 (72.1) | 231 (64.2) | 1763 (59.7) | 1503 (64.5) | 9654 (68.1) | |
| ER+HER2+ | 696 (8.2) | 52 (14.4) | 401 (13.6) | 213 (9.1) | 1362 (9.6) | |
| ER−HER2+ | 274 (3.2) | 15 (4.2) | 207 (7.0) | 113 (4.8) | 609 (4.3) | |
| ER−HER2− | 592 (6.9) | 18 (5.0) | 254 (8.6) | 190 (8.1) | 1054 (7.4) | |
| Inconclusive | 818 (9.6) | 44 (12.2) | 328 (11.1) | 313 (13.4) | 1503 (10.6) | |
| Chemotherapy | <0.001 | |||||
| No | 5548 (65.0) | 147 (40.8) | 863 (29.2) | 1767 (75.8) | 8325 (58.7) | |
| Yes | 2989 (35.0) | 213 (59.2) | 2090 (70.8) | 565 (24.2) | 5857 (41.3) | |
| Biological therapy | <0.001 | |||||
| No | 7681 (90.0) | 287 (79.7) | 2369 (80.2) | 2116 (90.7) | 12 453 (87.8) | |
| Yes | 856 (10.0) | 73 (20.3) | 584 (19.8) | 216 (9.3) | 1729 (12.2) | |
| Endocrine therapy | <0.001 | |||||
| No | 1333 (15.6) | 61 (16.9) | 688 (23.3) | 519 (22.3) | 2601 (18.3) | |
| Yes | 7204 (84.4) | 299 (83.1) | 2265 (76.7) | 1813 (77.7) | 11 581 (81.7) | |
| Deaths | ||||||
| Overall | 1265 (14.8) | 37 (10.3) | 926 (31.4) | 734 (31.5) | 2962 (20.9) | <0.001 |
| Breast cancer-specific | 450 (5.3) | 26 (7.2) | 604 (20.5) | 246 (10.5) | 1326 (9.3) | <0.001 |
Values are n (%) unless otherwise indicated. *Pathological stage used for primary surgery patients and pretreatment clinical stage used for neoadjuvant chemotherapy patients. sBCS, standard breast-conserving surgery; RTx, radiotherapy; OBCS, oncoplastic breast-conserving surgery; MTx, mastectomy; SMID, Scottish Index of Multiple Deprivation; ER, oestrogen receptor; HER2, human epidermal growth factor receptor-2.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
